Target
Avelumab
11 abstracts
Abstract
Informing optimal treatment (tx) sequences for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the United States: Results of a clinical simulation modeling exercise.Org: Evidera, Inc, EMD Serono Research & Development Institute, The Healthcare Business of Merck KGaA,
Abstract
Effect of antibiotic, proton pump inhibitor, H2 blocker, metformin and statin use on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.Org: John D. Dingell VA Hospital,
Abstract
Maintenance therapy with avelumab as the first-line treatment in patients with metastatic urothelial carcinoma: A real-world, ambispective RAVE-Bladder study.Org: Moscow City Oncological Hospital No.1, Krasnoyarsk Regional Clinical Oncological Dispensary Named After A.I. Kryzhanovsky, Clinical hospital #1, Medsi Otradnoe, SBHI Leningrad Regional Clinical Hospital,
Abstract
Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and single-arm meta-analysis.Org: Hospital do Servidor Público do Estado de São Paulo, Faculdade de Medicina de Barbacena FAME - FUNJOB, Centro de Oncologia do Paraná,
Abstract
Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC).Org: Kaiser Permanente Oakland Medical Center, Inova Schar Cancer Institute, Pfizer, Genesis Research, EMD Serono Research & Development Institute,
Abstract
Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.Org: University of Rochester Cancer Center & Wilmot Cancer Institute, Vaccinex, Inc., University of North Carolina at Chapel Hill,
Abstract
Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).Org: James P. Wilmot Cancer Center/URMC - JPWCC, Memorial Sloan Kettering Cancer Center,
Abstract
Safety of checkpoint inhibitors in older patients with genitourinary cancers.Org: University of Florida/UF Health Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics,
Abstract
Adrenal insufficiency in patients on immune checkpoint inhibitors: An All of Us Data study.Org: Harlem Hospital Center, New York Oncology Hematology PC,